CAS: 15687-37-3; Naftazone

该化合物是有效的,但也可能与非加新体的副作用有关,例如肠胃不适和潜在的心血管风险.与任何药物一样,它对于使用受医疗监督的纳夫区以确保安全和功效至关重要.

结构式图片

MSDS等安全信息

    上下游产品

    semicarbazide hydr°Chloride 1,2-naphthoquinone hydrazine carboxamideα-naphthol

    合成工艺路线路线简述

    • 合成目标产物 Naftazone 主要起始原料 Semicarbazide Hydrochloride And 1,2-Naphthoquinone
    • (文献来源)合成步骤主要原料 Semicarbazide Hydrochloride 和 1,2-Naphthoquinone
    📜S-(4-叔-丁基苯甲基)[2-(1-甲基丁基)吡啶-3-基]硫代氨基甲酸酯,1,2-萘醌 以 乙醇,水 用作溶剂,化学反应 4.0H,以78%的收率获得萘醌腙
    参考文献:含n-取代的硫代半脲/半脲的钌(III)配合物的合成,表征,抗氧化剂,细胞毒性和dna裂解研究
    标题:含n-取代的硫代半脲/半脲的钌(III)配合物的合成,表征,抗氧化剂,细胞毒性和dna裂解研究
    摘要:摘要报道了含ons / Ono三齿配体的钌(III)配合物的合成,表征和生物学研究.1,2-萘醌n-取代的硫半脲/半脲(hl N ; N = 1-4)与[rucl 3(eph 3)3 ](e = P或as)反应生成[rucl 2(eph 3)(l ñ )],通过元素分析,Ft-Ir,Uv-Vis,磁化率测量,Esr光谱,Esi-Ms,电化学研究和粉末x射线衍射图进行表征.通过涉及dpph和羟基自由基的抗氧化剂分析评估的自由基清除能力表明,该配合物具有出色的自由基清除性能.测定了该复合物对mcf-7和a431细胞系的体外细胞毒性,结果表明钌(III)复合物对选定的癌细胞表现出有效的细胞毒性活性.此外,发现复合物促进质粒pbr322 Dna的切割. 图形概要
    Doi:10.1007/s00706-013-1097-1

    海关参考信息

    专利信息


    专利号:US-2014315720-A1
    优先权日:2012-10-24
    标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
    发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
    权利人:CELANESE ACETATE LLC
    摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Rascol O, Ferreira J, Nègre-Pages L, Perez-Lloret S, Lacomblez L, Galitzky M, Lemarié JC, Corvol JC, Brotchie JM, Bossi L. A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease. Fundam Clin Pharmacol. 2012 Aug;26(4):557-64. doi: 10.1111/j.1472-8206.2011.00951.x. Epub 2011 May 18. doi: 10.4097/kjae.2014.66.3.240. Epub 2014 Mar 28.
    3: Walash MI, Belal F, El-Enany N, Eid M, El-Shaheny RN. Stability-indicating HPLC method for determination of naftazone in tablets. Application to degradation kinetics and content uniformity testing. J Chromatogr Sci. 2011 Aug;49(7):495-501. French.

    合成参考文献


    参考文献:10.1007/s40263-020-00754-0
    摘要:Gonzalez-Latapi P, Bhowmick SS, Saranza G, Fox SH. Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update. CNS Drugs. 2020 Oct;34(10):1025–44. doi: 10.1007/s40263-020-00754-0.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知